Jay Courtright

2.7k total citations
16 papers, 290 citations indexed

About

Jay Courtright is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Jay Courtright has authored 16 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Genetics and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Jay Courtright's work include CAR-T cell therapy research (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Biomedical Ethics and Regulation (3 papers). Jay Courtright is often cited by papers focused on CAR-T cell therapy research (6 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Biomedical Ethics and Regulation (3 papers). Jay Courtright collaborates with scholars based in United States, Sweden and Germany. Jay Courtright's co-authors include Joseph Bastian, J. Douglas Crawford, Julie R. Nangia, Cynthia Osborne, Polly Niravath, Mothaffar F. Rimawi, Frankie A. Holmes, Mario E. Lacouture, Tao Wang and Richard G. Paxman and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Jay Courtright

16 papers receiving 286 citations

Peers

Countries citing papers authored by Jay Courtright

Since Specialization

Citations

This map shows the geographic impact of Jay Courtright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Courtright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Courtright more than expected).

Fields of papers citing papers by Jay Courtright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Courtright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Courtright. The network helps show where Jay Courtright may publish in the future.

Co-authorship network of co-authors of Jay Courtright

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Courtright. A scholar is included among the top collaborators of Jay Courtright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Courtright. Jay Courtright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2022 ·Blood ·Yuliya Linhares, (unknown), Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, (unknown), (unknown), James Essell, Suzanne Fanning, Howard R. Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, (unknown), (unknown), (unknown), Bassam Mattar	4
2	Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2021 ·Transplantation and Cellular Therapy ·John E. Godwin, César O. Freytes, Michael B. Maris, Don A. Stevens, Daanish Hoda, Bassam Mattar, Juan Carlos Varela, Mohamad Cherry, James Essell, Jay Courtright, Suzanne Fanning, Habte Yimer, Nikolaus S. Trede, (unknown), James Lymp, Carlos Bachier	1
3	Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study 2021 ·Blood ·Ian W. Flinn, David Andorsky, Jason M. Melear, Sudhir Manda, Bertrand Anz, Kathryn S. Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas‐Ohlmayer, Suman Kambhampati, (unknown), John C. Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman	1
4	OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING 2021 ·Hematological Oncology ·John E. Godwin, (unknown), Michael B. Maris, Carlos Bachier, Don A. Stevens, Daanish Hoda, Juan Carlos Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Nikolaus S. Trede, (unknown), James Lymp, Paul Shaughnessy	1
5	Outreach: Preliminary safety and efficacy results from a phase 2 study of lisocabtagene maraleucel (liso-cel) in the nonuniversity setting. 2021 ·Journal of Clinical Oncology ·John E. Godwin, Bassam Mattar, Michael B. Maris, Carlos Bachier, Don A. Stevens, Daanish Hoda, Juan Carlos Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Nikolaus S. Trede, (unknown), James Lymp, Paul Shaughnessy	3
6	Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL) 2021 ·Blood ·John E. Godwin, Bassam Mattar, Michael B. Maris, Carlos Bachier, Don A. Stevens, Daanish Hoda, Juan Carlos Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, (unknown), (unknown), (unknown), K. OGASAWARA, (unknown), Paul Shaughnessy	8
7	Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study 2020 ·Blood ·Ian W. Flinn, David Andorsky, Jason M. Melear, Sudhir Manda, Bertrand Anz, Kathryn S. Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas‐Ohlmayer, Suman Kambhampati, (unknown), John C. Pesko, (unknown), (unknown), Jeff P. Sharman	2
8	Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study 2020 ·Blood ·John E. Godwin, César O. Freytes, Michael B. Maris, Don A. Stevens, Daanish Hoda, Bassam Mattar, Juan Carlos Varela, Mohamad Cherry, James Essell, Jay Courtright, Suzanne Fanning, Habte Yimer, Nikolaus S. Trede, (unknown), James Lymp, Carlos Bachier	3
9	CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Jeff P. Sharman, David Andorsky, Jason M. Melear, Sudhir Manda, Bertrand Anz, (unknown), John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas‐Ohlmayer, Suman Kambhampati, Dingfeng Jiang, John C. Pesko, (unknown), (unknown), (unknown), Ian W. Flinn	1
10	Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study 2019 ·Blood ·Jeff P. Sharman, David Andorsky, Jason M. Melear, Sudhir Manda, Bertrand Anz, Kathryn S. Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas‐Ohlmayer, Suman Kambhampati, (unknown), Todd M. Zimmerman, (unknown), (unknown), Dingfeng Jiang, Ian W. Flinn	4
11	Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer. 2017 ·Journal of Clinical Oncology ·Julie R. Nangia, Tao Wang, Cynthia R. Osborne, Polly Niravath, (unknown), Steven W. Papish, Frankie A. Holmes, Jame Abraham, Shari Goldfarb, Jay Courtright, Richard G. Paxman, (unknown), Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar F. Rimawi	2
12	Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer 2017 ·JAMA ·Julie R. Nangia, Tao Wang, Cynthia Osborne, Polly Niravath, (unknown), Steven W. Papish, Frankie A. Holmes, Jame Abraham, Mario E. Lacouture, Jay Courtright, Richard G. Paxman, (unknown), Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar F. Rimawi	143
13	286 POSTER Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237 2008 ·European Journal of Cancer Supplements ·(unknown), Peter J. Houghton, Christopher L. Morton, John M. Maris, Jay Courtright, Hernán Carol, Richard B. Lock, Yi Yang, Mark Manfredi	3
14	Commissural neurons of the electrosensory lateral line lobe of Apteronotus leptorhynchus: morphological and physiological characteristics 1993 ·Journal of Comparative Physiology A ·Joseph Bastian, Jay Courtright, J. Douglas Crawford	37
15	Morphological correlates of pyramidal cell adaptation rate in the electrosensory lateral line lobe of weakly electric fish 1991 ·Journal of Comparative Physiology A ·Joseph Bastian, Jay Courtright	71
16	Effects of Thyrotoxicosis on Mitochondrial Enzymes of Rat Soleus 1979 ·Hormone and Metabolic Research ·Jay Courtright, R. H. Fitts	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact